Phase II study of carboplatin and pemetrexed followed by gefitinib for patients with advanced non-small cell lung cancer harboring sensitive EGFR mutation.

被引：0
|
作者：
Manabe, Saki
Oshita, Fumihiro
Murakami, Shuji
Kondo, Tetsuro
Saito, Haruhiro
Kaneko, Takeshi
Yamada, Kouzo
机构：
[1] Kanagawa Canc Ctr, Dept Thorac Oncol, Yokohama, Kanagawa, Japan
[2] Kanagawa Prefectural Ashigarakami Hosp, Matsudo, Japan
[3] Kanagawa Canc Ctr, Yokohama, Kanagawa, Japan
[4] Yokohama City Univ, Grad Sch Med, Yokohama, Kanagawa, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_supll.e20581
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e20581
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Phase II study of a combination regimen of gefitinib and pemetrexed as first-line treatment in patients with advanced non-small cell lung cancer harboring a sensitive EGFR mutation
    Yoshimura, Naruo
    Kudoh, Shinzoh
    Mitsuoka, Shigeki
    Yoshimoto, Naoki
    Oka, Takako
    Nakai, Toshiyuki
    Suzumira, Tomohiro
    Matusura, Kuniomi
    Tochino, Yoshihiro
    Asai, Kazuhisa
    Kimura, Tatsuo
    Kawaguchi, Tomoya
    Hirata, Kazuto
    [J]. LUNG CANCER, 2015, 90 (01) : 65 - 70
  • [2] Study of Gefitinib and Pemetrexed as First-Line Treatment in Patients with Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutation
    An, Chaolun
    Zhang, Jiajun
    Chu, Hongjun
    Gu, Chunyan
    Xiao, Feng
    Zhu, Fengwei
    Lu, Rujian
    Shi, Hai
    Zhang, Hongfei
    Yi, Xin
    [J]. PATHOLOGY & ONCOLOGY RESEARCH, 2016, 22 (04) : 763 - 768
  • [3] A phase II trial of gefitinib monotherapy in pretreated patients with advanced non-small cell lung cancer not harboring activating EGFR mutations: implications of sensitive EGFR mutation test
    Choi, Moon Ki
    Hong, Jung Yong
    Chang, Won Jin
    Kim, Moon Jin
    Kim, Sung Min
    Jung, Hyun Ae
    Do, In-Gu
    Choi, Yoon-la
    Sun, Jong-Mu
    Ahn, Jin Seok
    Park, Keunchil
    Ahn, Myung-Ju
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 75 (06) : 1229 - 1236
  • [4] A phase II trial of gefitinib monotherapy in pretreated patients with advanced non-small cell lung cancer not harboring activating EGFR mutations: implications of sensitive EGFR mutation test
    Moon Ki Choi
    Jung Yong Hong
    Won Jin Chang
    Moon Jin Kim
    Sung Min Kim
    Hyun Ae Jung
    In-Gu Do
    Yoon-la Choi
    Jong-Mu Sun
    Jin Seok Ahn
    Keunchil Park
    Myung-Ju Ahn
    [J]. Cancer Chemotherapy and Pharmacology, 2015, 75 : 1229 - 1236
  • [5] Randomized phase II study of pemetrexed plus carboplatin followed by pemetrexed versus paclitaxel plus carboplatin followed by pemetrexed in advanced nonsquamous, non-small cell lung cancer (LOGIK 0904)
    Takayama, Koichi
    Inoue, Koji
    Takeshita, Masafumi
    Tashiro, Naoki
    Harada, Taishi
    Seto, Takashi
    Imanaga, Tomotoshi
    Fujimoto, Noriko
    Nakagaki, Noriaki
    Kawasaki, Masayuki
    Kishimoto, Junji
    Ichinose, Yukito
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [6] RANDOMIZED PHASE II STUDY OF PEMETREXED PLUS CARBOPLATIN FOLLOWED BY PEMETREXED VERSUS PACLITAXEL PLUS CARBOPLATIN FOLLOWED BY PEMETREXED IN ADVANCED NON-SQUAMOUS, NON-SMALL CELL LUNG CANCER (LOGIK 0904)
    Shiraishi, Yoshimasa
    Inoue, Koji
    Takeshita, Masafumi
    Harada, Taishi
    Tashiro, Naoki
    Seto, Takashi
    Imanaga, Tomotoshi
    Fujimoto, Noriko
    Nakagaki, Noriaki
    Kawasaki, Masayuki
    Kishimoto, Junji
    Takayama, Koichi
    Ichinose, Yukito
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S403 - S404
  • [7] Randomized Phase II Study of Pemetrexed Versus Gefitinib in Previously Treated Patients with Advanced Non-small Cell Lung Cancer
    Kim, Young Saing
    Cho, Eun Kyung
    Woo, Hyun Sun
    Hong, Junshik
    Ahn, Hee Kyung
    Park, Inkeun
    Sym, Sun Jin
    Kyung, Sun Young
    Kang, Shin Myung
    Park, Jeong-Woong
    Jeong, Sung Hwan
    Park, Jinny
    Lee, Jae Hoon
    Shin, Dong Bok
    [J]. CANCER RESEARCH AND TREATMENT, 2016, 48 (01): : 80 - 87
  • [8] A randomized phase II study comparing erlotinib with or without bevacizumab in patients with advanced non-small cell lung cancer (NSCLC) with EGFR mutation.
    Lee, Youngjoo
    Kim, Hye Ryun
    Hong, Min Hee
    Lee, Ki Hyeong
    Park, Keon Uk
    Lee, Geon Kook
    Kim, Hyae Young
    Lee, Soo-Hyun
    Lim, Kun Young
    Yoon, Sung Jin
    Cho, Byoung Chul
    Han, Ji-Youn
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [9] A phase II trial of gefitinib monotherapy in pretreated patients with advanced non-small cell lung cancer not harboring activating EGFR mutations.
    Choi, Moon Ki
    Hong, Jung Yong
    Chang, Won Jin
    Kim, Moonjin
    Kim, Sungmin
    Jung, Hyun Ae
    Lim, Sung Hee
    Lee, Ji Yun
    Do, Ingu
    Chol, Yoon-La
    Sun, Jong-Mu
    Ahn, Jin Seok
    Park, Kounchil
    Ahn, Myung-Ju
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [10] Anlotinib with gefitinib as first-line therapy in advanced non-small cell lung cancer harboring EGFR mutations: A phase II study
    Ji, Y.
    Wang, X.
    Lou, Z.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S979 - S979
12345